Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

ConclusionNo significant increases in TEAEs were detected in nangibotide-treated patients versus placebo. These results encourage further evaluation of nangibotide and further exploration of plasma sTREM-1 concentrations as a predictive efficacy biomarker.
Source: Intensive Care Medicine - Category: Intensive Care Source Type: research